Trial Condition(s):

Colorectal Neoplasms

Regorafenib post-marketing surveillance

Bayer Identifier:

16472

ClinicalTrials.gov Identifier:

NCT01843400

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for colorectal cancer.
The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice.
A total of 1,250 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient.

Inclusion Criteria
Patients 
 - who are determined to start Regorafenib/ STIVARGA treatment
Exclusion Criteria
- Patients who have previously received Regorafenib/ STIVARGA

Trial Summary

Enrollment Goal
1301
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Stivarga (Regorafenib, BAY73-4506)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design